What is Generation Bio?
Generation Bio Co. is a biotechnology firm headquartered in Cambridge, Massachusetts, dedicated to creating non-viral genetic medicines for both rare and prevalent diseases. The company's proprietary technology centers on its cell-targeted lipid nanoparticle (ctLNP) platform, designed for precise delivery of nucleic acids to specific tissues and cell types, thereby avoiding off-target clearance by the liver and spleen. Complementing this is their novel immune-quiet DNA (iqDNA) technology, which facilitates long-lasting gene expression from non-integrating episomes and bypasses innate immune sensors that have historically hindered DNA's use in non-viral systems. Generation Bio is leveraging this platform to develop a pipeline of treatments for conditions including cancer, autoimmune disorders, and hematologic diseases, with a particular focus on sickle cell disease, beta-thalassemia, and hemophilia A. The company, formerly known as Torus Therapeutics, Inc., was incorporated in 2016.
How much funding has Generation Bio raised?
Generation Bio has raised a total of $235M across 3 funding rounds:
Series A
$25M
Series B
$100M
Series C
$110M
Series A (2016): $25M, investors not publicly disclosed
Series B (2018): $100M, investors not publicly disclosed
Series C (2020): $110M supported by Invus, T. Rowe Price, Deerfield, Foresite Capital, Fidelity, Wellington Management Company, Casdin, Farallon, and Atlas Venture
Key Investors in Generation Bio
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services, founded in 1985 and headquartered in New York City, New York.
T. Rowe Price
Founded in 1937, T.Rowe Price Group provides investment services to a diverse client base, managing equity and fixed income mutual funds globally from its Baltimore, Maryland headquarters.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models and driving innovation.
What's next for Generation Bio?
The substantial enterprise-level funding received by Generation Bio positions it for accelerated development and scaling of its innovative genetic medicine programs. This strategic investment is likely to fuel further research and clinical trials, particularly for its prioritized indications such as sickle cell disease and beta-thalassemia. The company's focus on a non-viral delivery system and immune-quiet DNA technology suggests a strategic aim to overcome existing challenges in gene therapy, potentially offering a more durable and safer therapeutic approach. Future endeavors will likely involve advancing its pipeline through regulatory pathways and expanding its therapeutic reach to other target diseases and tissues.
See full Generation Bio company page
